El efecto de los anti inflamatorios no esteroideos sobre el espesor retiniano, la inflamación y la agudeza visual posterior a la extracción de catarata
PDF

Palabras clave

Antiinflamatorios no esteroideos
Edema macular
Facoemulsificación
Nepafenac
Cirugía de catarata
Inflamación Anti Inflammatory agents
Non steroidal
Macular edema
Phacoemulsification
Nepafenac
Cataract surgery
Inflammation

Cómo citar

Gaviria, J. G., Cabrera, M., Rodríguez, F., Valencia, M., Rodríguez, M., Silva, T., Chaves, A., & Torres, C. . (2011). El efecto de los anti inflamatorios no esteroideos sobre el espesor retiniano, la inflamación y la agudeza visual posterior a la extracción de catarata. Revista Médica Sanitas, 14(4), 40-47. Recuperado a partir de //revistas.unisanitas.edu.co/index.php/rms/article/view/352

Resumen

Objetivos: comparar la inflamación, el espesor retiniano, la agudeza visual mejor corregida (AVCC) y la incidencia de edema macular postcirugía de catarata, en ojos tratados con nepafenac, dexametasona o la combinación de los dos. Métodos: estudio prospectivo, aleatorizado, controlado y ciego para el observador. Se aleatorizaron 147 ojos con catarata para recibir dexametasona 0.1% cada 6 horas por 12 días de forma postoperatoria, nepafenac 0.1% cada 8 horas antes de la cirugía y por 15 días postoperatorios o la combinación de los dos. Los desenlaces medidos fueron miosis intraoperatoria, presión intraocular a la primera y sexta semana, AVCC postoperatoria, volumen macular total, espesor foveal y perifoveal medidos por tomografía óptica coherente, y la presencia o ausencia de edema macular (espesor foveal > 240 micras) en la sexta semana. Resultados: el grupo dexametasona presentó mayor miosis intraoperatoria que el grupo nepafenac (p0.05). Conclusión: los tres esquemas son efectivos y seguros para prevenir la inflamación postoperatoria. El uso de nepafenac conlleva menor miosis intraoperatoria y especialmente como monoterapia, en menor presión intraocular a la primera semana postoperatoria y menor espesor perifoveal.

PDF

Citas

Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557-634.

Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007 Sep;33(9):1550-1558. https://doi.org/10.1016/j.jcrs.2007.05.013

Stewart R, Grosserode R, Cheetham JK, Rosenthal A. Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery. Clin Ther. 1999 Abr;21(4):723-732. https://doi.org/10.1016/S0149-2918(00)88323-X

Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007 Sep;33(9):1539-1545. https://doi.org/10.1016/j.jcrs.2007.05.015

Deschenes J, Murray PI, Rao NA, Nussenblatt RB. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul. Immunol. Inflamm. 2008;16:1-2. https://doi.org/10.1080/09273940801899822

Kim SJ, Belair M-L, Bressler NM, Dunn JP, Thorne JE, Kedhar SR, et al. A method of reporting macular edema after cataract surgery using optical coherence tomography. Retina (Philadelphia, Pa.). 2008;28:870-876. https://doi.org/10.1097/IAE.0b013e318169d04e

Lane SS, Modi SS, Lehmann RP, Holland EJ. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007;33:53-58. https://doi.org/10.1016/j.jcrs.2006.08.043

Nardi M, Lobo C, Bereczki A, Cano J, Zagato E, Potts S, et al. Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery. Clin Ophthalmol. 2007 ;1:527-533.

Asano S, Miyake K, Ota I, Sugita G, Kimura W, Sakka Y, et al. Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after smallincision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. J Cataract Refract Surg. 2008;34:57-63. https://doi.org/10.1016/j.jcrs.2007.08.030

Miyanaga M, Miyai T, Nejima R, Maruyama Y, Miyata K, Kato S. Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmol. 2009;87:300-305. https://doi.org/10.1111/j.1755-3768.2008.01433.x

Ray S, D'Amico DJ. Pseudophakic cystoid macular edema. Semin Ophthalmol. 2002;17:167-80. https://doi.org/10.1076/soph.17.3.167.14794

Guzek JP, Holm M, Cotter JB, Cameron JA, Rademaker WJ, Wissinger DH, et al. Risk factors for intraoperative complications in 1000 extracapsular cataract cases. Ophthalmology. 1987;94:461-466. https://doi.org/10.1016/S0161-6420(87)33424-4

Solomon KD, Turkalj JW, Whiteside SB, Stewart JA, Apple DJ. Topical 0.5% ketorolac vs 0.03% flurbiprofen for inhibition of miosis during cataract surgery. Arch. Ophthalmol. 1997;115:1119-1122. https://doi.org/10.1001/archopht.1997.01100160289004

Antcliff RJ, Trew DR. The maintenance of per-operative mydriasis in phacoemulsification with topical diclofenac sodium. Eye (Lond). 1997;11 ( Pt 3):389-391. https://doi.org/10.1038/eye.1997.82

Cervantes-Coste G, Sánchez-Castro YG, OrozcoCarroll M, Mendoza-Schuster E, Velasco-Barona C. Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clin Ophthalmol. 2009;3:219-226. https://doi.org/10.2147/OPTH.S4820

Donnenfeld ED, Perry HD, Wittpenn JR, Solomon R, Nattis A, Chou T. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. J Cataract Refract Surg. 2006;32:1474-1482. https://doi.org/10.1016/j.jcrs.2006.04.009

Yavas GF, Oztürk F, Küsbeci T. Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. J Cataract Refract Surg. 2007;33:804-807. https://doi.org/10.1016/j.jcrs.2007.01.033

Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch. Ophthalmol. 2006;124:193-198. https://doi.org/10.1001/archopht.124.2.193

Wexler A, Sand T, Elsås TB. Macular thickness measurements in healthy Norwegian volunteers: an optical coherence tomography study. BMC Ophthalmol. 2010;10:13. https://doi.org/10.1186/1471-2415-10-13

Biro Z, Balla Z, Kovacs B. Change of foveal and perifoveal thickness measured by OCT after phacoemulsification and IOL implantation. Eye (Lond). 2008;22:8-12. https://doi.org/10.1038/sj.eye.6702460

Perente I, Utine CA, Ozturker C, Cakir M, Kaya V, Eren H, et al. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography. Curr. Eye Res. 2007;32:241- 247. https://doi.org/10.1080/02713680601160610

Degenring RF, Vey S, Kamppeter B, Budde WM, Jonas JB, Sauder G. Effect of uncomplicated phacoemulsification on the central retina in diabetic and non-diabetic subjects. Graefes Arch. Clin. Exp. Ophthalmol. 2007;245:18-23. https://doi.org/10.1007/s00417-006-0377-4

Descargas

Los datos de descargas todavía no están disponibles.